reports, hTERT mutations were more frequent in older patients (p < 0.0001), being found only in 5 patients <20 years of age. In addition, hTERT-mutated tumors were more frequently recurrent (p = 0.026) and hTERT mutations were significantly enriched in tumors located in the right cerebellar hemisphere (p = 0.039). No mutations were found on the H3F3A or HIST1H3B genes. hTERT promoter mutations are frequent in medulloblastoma and are associated with older patients, prone to recurrence and located in the right cerebellar hemisphere. On the other hand, histone 3 mutations do not seem to be present in medulloblastoma.
ulates telomerase activity [2, 3] . Although telomerase is normally silenced in somatic cells, it is active in male germ cells, activated lymphocytes, stem cell populations and during development [4] [5] [6] . In the large majority of human cancers, abnormal telomerase reactivation is observed, leading to telomere maintenance and limitless proliferative potential [7] [8] [9] .
Hotspot activating mutations were recently described in the hTERT promoter region in a variety tumor types, including medulloblastomas (20%) and glioblastomas (83%) among many others [10] [11] [12] . These mutations are located in 2 positions, c.-124:G>A and c.-146:G>A, and are thought to be the main biological mechanism responsible for telomerase overexpression [13, 14] . The functional consequence of the presence of promoter mutations was initially associated with the creation a new binding motif for E-twenty-six (ETS) transcription factors and ternary complex factors (TCFs) near the transcription start, leading to an increased transcription of the hTERT promoter of at least 2-fold, as assessed by reporter assays [13, 14] . Recently, it was also demonstrated that the occurrence of these mutations leads to the recruitment of the GABP transcription factor, and the activation of transcription and aberrant expression of hTERT in several cancers [15] . In addition to these mutations, a common functional single nucleotide polymorphism (SNP), rs2853669, located in the hTERT promoter has been shown to influence the prognostic value of the mutations mentioned in gliomas and bladder and renal cell carcinomas [16] .
Alternative lengthening of telomeres (ALT) pathways has also been described, being present in 15% of cancers. Inactivating ATRX mutations, associated with histone H3 mutations, were described in tumors with ALT phenotype, including 1.5% of medulloblastoma [17] . These mutations were reported to be responsible for disrupting the histone code and affecting the regulation of transcription [18] . Mutations in histone 3 ( H3F3A , encoding H3.3 and HIST1H3B , encoding H3.1) have been reported in higher frequencies in pediatric gliomas of different histologies, but have not been extensively studied in medulloblastoma [18] [19] [20] .
In this work, we investigated the clinical relevance of these important regulators in medulloblastoma, confirming that hTERT promoter mutations are a frequent event in medulloblastoma. These mutations were associated with older age, tumor recurrence and tumors from the right cerebellar hemisphere. On the other hand, histone mutations do not seem to be present in this type of brain tumor.
Material and Methods
Tumor Samples and DNA Isolation Formalin-fixed, paraffin-embedded (FFPE) medulloblastoma samples from 68 patients, i.e. 68 primary tumors and 1 recurrence (with a matched primary tumor sample) aged 1.5-70 years, were obtained after approval by local and multicenter ethical review committees at the Laboratory of Neuropathology, Hospital of Santa Maria (CHLN), Lisbon, Portugal, and the Federal University of São Paulo, São Paulo, and Barretos Cancer Hospital, Barretos, Brazil. All the samples enrolled in the study were unlinked and unidentified from their donors. Due the retrospective nature of the study, no written informed consent from patients was obtained. The presence of tumor tissue in the samples and the tumor histology was verified on an H&E-stained section by the pathologists J.N.S., J.P. and G.C.A.
DNA was isolated using the QIAamp DNA mini kit (Qiagen) according to the manufacturer's instructions and as previously reported [21] .
Mutation Analysis hTERT promoter mutations were screened using the primers previously described [22] that amplify the sites of the c.-124:G>A and c.-146:G>A mutations, as previously described [12, 23, 24] .
Histone 3 hotspot regions previously identified [18, 19] were amplified with the following primers: H3F3A (forward: 5 ′ -CAT-GGCTCGTACAAAGCAGA; reverse: 5 ′ -CAAGAGAGACTTTG-TCCCATTTTT) and HIST1H3B (forward: 5 ′ -TT TC CT TT CC-TCCACAGACG; reverse: 5 ′ -CGGTAACGGTGAGGCTTTT).
Amplification of PCR products was confirmed by gel electrophoresis. Subsequently, samples were Sanger-sequenced after PCR product purification with ExoStar (Invitrogen). Sequencing PCR was performed using the ABI PRISM 3730xL DNA analyzer (Applied Biosystems, USA) by STAB VIDA services (Portugal).
Statistical Analysis
All statistical tests were done in SPSS v20.0 (SPSS Inc.). Correlations between categorical values were done using the 2-tailed χ 2 test and the Fisher exact test. Continuous variables were assessed using the Mann-Whitney U test. Associations between hTERT mutational status and patients' overall survival were analyzed using the Kaplan-Meier method and the log-rank test. A p value of <0.05 was considered significant.
Results

hTERT Is Frequently Mutated in Medulloblastoma
We successfully sequenced hTERT in 69 FFPE medulloblastomas, corresponding to 68 primary tumors and 1 recurrence. Of these, 35 samples were from pediatric patients (1.5-17 years of age) and 32 from adults (>18 years); for an additional sample we could not confirm the age at diagnosis. We identified a total of 19 cases (27.5%) with hTERT promoter mutations ( Similarly to previous reports [10, 11] , hTERT mutations were more frequent in older patients ( table 2 ; p < 0.0001), being found in only 3 patients younger than 17 years (3/35, 8.6%), whereas >50% of the adult patients presented with hTERT promoter mutations (18/32, 56.3%). In addition, hTERT-mutated tumors were more frequently in the recurrent cases (p = 0.026), and hTERT mutations were significantly enriched in the tumors located in the right cerebellar hemisphere (p = 0.039). No other clinicopathological features were found to be statistically significant ( table 2 ; p > 0.05).
The polymorphism rs2853669 was successfully sequenced in 41 of the 69 samples, and was present in 41.5% of the cases. Although this polymorphism has been described as modifying the survival of mutant carriers [16] , we could not confirm these results in our cohort as only 6 samples presenting the variant also had survival data. No differences were seen between wild-type (WT) and mutated samples regarding overall survival ( fig. 2 ; 
Discussion
Promoter mutations of the hTERT gene were first described in melanoma in 2 distinct reports [13, 14] . Since then, hTERT promoter mutations have been described across several tumor types, and are one of the most frequent genetic alterations involved in human tumorigenesis [12, 25] .
In this study, we demonstrate that 28% of our medulloblastoma samples presented hTERT hotspot promoter mutations, in line with previous reports (18-33%) [10, 11, 25, 26] . These mutations were more frequent in older patients (p < 0.0001), were not seen in any infants (aged <4 years) and were only present in 3 children of 12, 14 and 16 years of age. Previous reports have shown the same trend, with Koelsche et al. [26] reporting 3 and 65% of these mutations, respectively, in pediatric and adult patients. This is line with the literature that demonstrates clinical and molecular characteristics distinguishing pediatric and adult medulloblastomas [27] . hTERT mutations have been described to be associated with less metastatic medulloblastoma at diagnosis [10] , and we have shown that these tumors were more prone to recurrence Mutations in histone 3 leading to K27M and G34R/ G34V have been extensively reported in pediatric highgrade gliomas [18, 19] . In spite of this, not many works have reported the results of these mutations in medulloblastomas. In 2014, Huether et al. [20] studied >1,000 different pediatric cancers, 70 of which were medulloblastomas, and did not see histone mutations in this brain tumor type. Similarly, we successfully sequenced approximately 60 samples for the hotspot mutations of HIST1H3B and H3F3A and found no mutations in our samples. Currently, it is well accepted that medulloblastomas can be cytogenetically and molecularly stratified into distinct subgroups that are associated with distinct clinicopathological features [28, 29] . hTERT mutations have been reported more frequently in the SHH molecular subgroup [10] , but further studies are needed to validate whether they are associated with particular cytogenetic and molecular subtypes.
In conclusion, we reported that hotspot hTERT mutations are present in approximately 1/3 of medulloblastomas cases and are associated with older patients and recurrent tumors, constituting a potential biomarker for medulloblastomas.
